Background. On the basis of meta-analyses, concern has been raised regarding a possible signal of increased mortality associated with the use of cefepime versus other b-lactam antibiotics. To further investigate this possible signal, we accessed findings and data from published and unpublished cefepime clinical trials.
and is the only antibacterial agent approved as monotherapy for this indication in the United States. Cefepime is included as a recommended therapy in treatment guidelines for febrile neutropenia [1] .
An increased risk of mortality associated with cefepime use has been reported in 2 previously published meta-analyses. Paul et al [2] published a trial-level meta-analysis in 2006 based on 17 publications reporting increased 30-day mortality with cefepime relative to other b-lactams when used for empiric antibacterial monotherapy for febrile neutropenia (risk ratio [RR], 1.44; 95% confidence interval [CI], 1.06-1.94). In 2007, the same group (Yahav et al [3] ) published a triallevel meta-analysis based on 57 publications that showed increased 30-day mortality associated with cefepime, compared with other b-lactams (RR, 1.26; 95% CI, 1.08-1.49), for the following clinical conditions combined: febrile neutropenia, pneumonia, urinary tract or gynecologic infections, and other or mixed infections [3] . This finding was based on mortality data from 41 of the 57 publications, because mortality data were missing from 16 publications; higher mortality rates were also noted in the subset of 19 febrile neutropenia publications (RR, 1.42; 95% CI, 1.09-1.84). The 2007 meta-analysis included 15 of the 17 cefepime publications from the 2006 meta-analysis; 2 publications were excluded because the trials were quasi-randomized.
Because of concern regarding the possible increased risk of mortality associated with cefepime use, we conducted a metaanalysis accessing both published and unpublished cefepime clinical trial data and findings. Our primary objective was to examine whether cefepime use was associated with an increased risk of mortality relative to the comparator drugs in randomized controlled trials. Our secondary objective was to examine whether the risk of mortality was associated with covariates such as clinical condition treated, comparator drug(s), and demographic and baseline risk factors (eg, presence of a microbiologically documented pathogen, baseline pathogen susceptibility, presence of renal failure, active malignant neoplasm, and bone marrow transplant). To gain a better understanding of the causes of death, including the possibility of lack of drug efficacy, we reviewed the case report forms (CRFs) of all patients who died in the febrile neutropenia trials that had previously been submitted to the FDA for registration purposes.
METHODS
We attempted to develop a complete list of all clinical trials of cefepime encompassing all published and unpublished trials, including those not previously submitted to the FDA. We also attempted to obtain mortality data that were missing from 16 of the 57 publications included in the 2007 meta-analysis described herein [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Information gleaned from this process was used to define the set of trials included in our meta-analyses.
Both patient-and trial-level data were sought from the pharmaceutical sponsor and from the authors of the publications. Trial-level data included information by trial regarding number of patients, number of deaths, clinical condition treated, and comparator drug(s) used. In addition, the patient-level data included variables for patient and trial identification, age, sex, race, study location, and any of the following present at baseline: any pathogen recovered, all isolated pathogens susceptible to study therapy, presence of a fungal pathogen, whether an infection was monomicrobial or polymicrobial, presence of renal insufficiency or failure, active malignant neoplasm, and history of bone marrow transplantation.
Trials were characterized on the basis of level of data (patient vs trial), whether mortality data were based on the intent-totreat (preferred due to randomization protection) or the clinically evaluable subset population, whether mortality rates were based on actual patients versus episodes of therapy (febrile neutropenia trials only), phase of trials, clinical condition treated, comparator agent(s) used, combination regimen used (if applicable), use of blinding, duration of follow-up, and inclusion in the 2007 meta-analysis.
A statistical analysis plan was developed before performing the meta-analysis. In our meta-analysis, we included the following: (1) all parallel-arm, randomized, active-controlled trials con- ducted with cefepime with or without adjunct therapy; (2) all US and non-US trials, including those not previously submitted to the FDA; and (3) trials with at least 10 patients per treatment arm. Figures 1 and 2 outline the process used to select trials included in the trial-and patient-level meta-analyses. To include trials with no deaths in both treatment arms, meta-analysis was performed using the Mantel-Haenszel adjusted risk difference (ARD) method (Comprehensive Meta Analysis, version 2.2; BioStat), which uses a weighted average based on each trial's size and magnitude of point estimate [20] . The ARD and 95% CIs were calculated using a fixed-effects model. The primary endpoint was all-cause mortality 30-days after therapy. Several sensitivity analyses (eg, exact method for odds ratio and Cox proportional hazards model stratified by trial) were conducted to check the robustness of the findings [21] . A sensitivity analysis using a random-effects model was also performed.
The 7 comparative febrile neutropenia trials with patientlevel data were reviewed in further detail to evaluate the cause(s) of death. This included the review of all CRFs from patients who died in the febrile neutropenia trials and analyses based on available clinical trial data. From these sources, we attempted to identify the most likely cause(s) of death for each patient and potential contributing factors (comorbidities, adverse events, and documented pathogens). Adverse events of special interest were identified and reviewed, including those associated with death, such as neurologic impairment or seizure, renal toxic effects, liver toxic effects, study drug failure, and central nervous system hemorrhage.
RESULTS
Trial-level analysis. Eighty-eight randomized, comparative trials, comprising 9467 cefepime-treated patients and 8288 comparator patients, were included in the trial-level analysis. Table 1 gives the number of trials and patients in each of the treatment groups by clinical condition treated. The febrile neutropenia and pneumonia trials comprised 30.7% and 22.80% of the total trial-level study population, respectively. Overall, 588 (6.21%) of 9467 cefepime-treated patients died within 30 days, compared with 497 (6.00%) of 8288 comparator patients. Meta-analysis based on these 88 trials showed no significant difference in mortality between cefepime-treated and comparator patients with an ARD per 1000 population of 5.38 (95% CI, Ϫ1.53 to 12.28). A sensitivity analysis using a randomeffects model was consistent with the primary analysis. Figure 3 shows the ARDs per 1000 population and corresponding 95% CIs for the overall population and by the clinical conditions treated. The point estimates for mortality for the clinical conditions of febrile neutropenia, pneumonia, and skin and skin structure infections favored comparators. These were post hoc subgroup analyses, and the numbers of deaths and patients in some clinical conditions (eg, skin structure infections) were relatively small (6/335 for cefepime vs 0/165 for comparators). The point estimates for mortality for intra-abdominal infections and urinary tract infections favored cefepime.
For the subgroup analysis by comparator antibacterials, 5 groups were prespecified as follows: ceftazidime, piperacillintazobactam, imipenem-meropenem, ceftriaxone-cefotaxime, and "other" (eg, mezlocillin, mezlocillin-gentamicin, cefuroxime, sulbactam-cefoperazone, clindamycin-gentamicin, and amikacin). Results of this analysis are shown in Figure 4 .
Patient-level analysis. We were able to obtain patient-level data from 39 trials. Patient-level data from 4 of these trials were not used in the final patient-level meta-analysis per our statistical analysis plan because these trials included fewer than 10 patients in at least 1 of the treatment arms ( Figure 2 ). Therefore, 35 randomized, comparative trials were available for the patient-level analysis, with a total of 5058 cefepime-treated patients and 3976 comparator patients. Table 2 gives the number of trials and patients by treatment group and clinical condition treated. Patients with febrile neutropenia, intra-abdominal infection, and pneumonia were the largest groups, comprising 15.52%, 11.14%, and 10.13% of the study population, respectively. Cefepime-and comparatortreated patients were similar with respect to demographic characteristics (eg, age, sex, and race) and baseline study characteristics (eg, pathogen recovered at baseline, pathogen susceptibility, and malignant neoplasm type) (Tables 3 and 4) .
Overall, 285 (5.63%) of 5058 cefepime-treated patients died within 30 days, compared with 226 (5.68%) of 3976 comparator patients. Meta-analysis of these 35 trials did not show a statistically significant increase in mortality in cefepime-treated patients (ARD per 1000 population, 4.83; 95% CI, Ϫ4.72 to 14.38). Subgroup analyses by demographic characteristics did not demonstrate significant mortality differences between cefepime-and comparator-treated patients.
Additional post hoc subgroup analyses were performed. Thirty-day, all-cause mortality in US trials with patient-level data was 4.36% (144/3299) for cefepime-treated patients and 4.70% (121/2593) for comparator patients (ARD per 1000 population, 1.59; 95% CI, Ϫ9.21 to 12.38). Thirty-day, all-cause mortality in non-US trials with patient-level data was 8.01% (141/1759) for cefepime-treated patients and 7.59% (105/1383) for comparator patients (ARD per 1000 population, 11.49; 95% CI, Ϫ6.77 to 29.75). Figure 5 displays an additional subgroup analysis for US and non-US trials according to whether the clinical condition treated was FDA approved or not.
Febrile neutropenia trials. The ARD per 1000 population in the subset of 24 febrile neutropenia trials included in our 
DISCUSSION
Our analysis did not demonstrate statistically significantly higher 30-day, all-cause mortality rates in cefepime-treated patients, compared with those treated with other antibacterial drugs in randomized controlled trials. This finding was consistent in both trial-level and patient-level analyses. Although not statistically significant, the point estimates in the overall population and in several subgroups, notably the subset of febrile neutropenia trials, did not favor cefepime. The results of the subgroup analyses should be interpreted with caution given the caveats of post hoc subgroup analyses, the small numbers of patients, and the few deaths in these subgroups. On the basis of our analysis of patient-level data and CRFs, we did not identify a biologically plausible explanation for increased risk of mortality in cefepime-treated patients. Our overall findings were not consistent with the trial-level meta-analyses published by Paul et al [2] in 2006 and Yahav et al [3] in 2007. The 41 publications in the Yahav et al [3] 2007 meta-analysis were based on 38 trials; our trial-level metaanalysis included these 38 trials plus 50 additional trials that were not included in their analysis. These 50 trials included 5517 cefepime-treated patients and 4484 comparator-treated patients. We successfully obtained additional mortality data for 11 of 16 publications for which mortality data were not available in the 2007 Yahav et al [3] meta-analysis. Subset analysis of 38 trials included in our meta-analysis and the 2007 Yahav et al [3] meta-analysis showed an increased risk of mortality between cefepime-treated and comparator patients (ARD per 1000 population, 17.02; 95% CI, 5.54-28.50), whereas the subset analysis of the 50 trials that were included in our metaanalysis but not the Yahav et al [3] 2007 analysis did not show a statistically significant difference in mortality (ARD per 1000 population, Ϫ2.8; 95% CI, Ϫ11.47 to 5.80). We examined the distribution of patients by clinical conditions treated to further understand the differences between the subset of 38 trials included in the Yahav et al [3] 2007 metaanalysis and the subset of 50 additional trials included only in our analysis. In the 38-trial subset (included in both the 2007 Yahav et al [3] and our meta-analyses), there was a larger proportion of patients with febrile neutropenia (53.4%), compared with 14.5% in the 50-trial subset (included only in our metaanalysis). The subset with 50 additional trials included 7 trials (628 cefepime-treated patients and 470 comparator patients) in which cefepime was evaluated for the treatment of intraabdominal infections. The Yahav et al [3] 2007 meta-analysis did not include any intra-abdominal infection trials, probably because these trials did not meet their predefined inclusion criteria of either a b-lactam comparator alone or combination therapy that included the addition of the same antibacterial to both treatment groups [3] . We included these trials in our analyses because we were evaluating the overall risk and benefit of cefepime use across all clinical conditions. The additional 50-trial subset included 15 trials in patients with "other" infections, such as bacterial meningitis, bacterial endocarditis, and bloodstream infections (2162 cefepime-treated patients and 2122 comparator patients), accounting for 40% of the population in this data set. In contrast, in the Yahav et al [3] 2007 meta-analysis, the "other" infections category accounted for 15% of the total population (7 trials, 560 cefepime-treated patients, and 562 comparators).
Regarding the analysis of febrile neutropenia trials, the statistically significant result noted by Yahav et al [3] in their analysis of 19 febrile neutropenia publications was not observed in our meta-analysis of 24 febrile neutropenia trials. Of note, only 2 of the 19 febrile neutropenia publications included in the Yahav et al [3] 2007 trial-level meta-analysis had statistically significantly increased mortality with cefepime use [22, 23] .
Other authors have explored the risk of mortality in cefepime clinical trials [23] [24] [25] [26] [27] . In September 2009, Gomez et al [24] noted that interim mortality data from a febrile neutropenia trial that they presented at a conference in 2001 were included in the Yahav et al [3] 2007 meta-analysis. In this trial, patients were randomized to receive either 2 g of cefepime every 12 h or 4 g of piperacillin-tazobactam every 8 h (both arms also received amikacin) [23] . Although, in the interim analysis, a statistically significantly higher mortality rate was seen in cefepime-treated patients, in their final analysis, no difference in 28-day, all-cause mortality was noted (7.8% [15/190] in the cefepime arm and 8.9% [17/190] in the piperacillin-tazobactam arm) [24] . Towne et al [25] reanalyzed mortality information from the 19 febrile neutropenia publications included in the 2007 Yahav et al [3] meta-analysis and were able to obtain information on the causes of death from 13 of these publications. They found no marked differences for infectious causes of death between cefepime-treated and comparator patients. They determined that none of the deaths were attributable to the antibacterial therapy administered and that more cefepime-treated patients died due to progression of underlying disease. In a retrospective cohort study of pediatric patients with acute myelogenous leukemia, Fisher et al [26] evaluated exposure to cefepime, ceftazidime, antipseudomonal penicillins, or carbapenems within the first year from acute myelogenous leukemia diagnosis. They found that cefepime exposure did not result in greater risk for in-hospital mortality when compared with other commonly used b-lactam antibacterials.
The strengths of our analysis included the following. First, because we were able to access data and results from unpublished trials submitted to the FDA for review and published studies, our meta-analysis included a larger number of clinical trials than did other published meta-analyses. Second, we obtained patient-level clinical trial data for a number of trials and were able to perform analyses based on these patient-level data in addition to those based on trial-level data. Third, the overall findings were consistent across both trial-level and patient-level analyses. For febrile neutropenia trials with patient-level data, we reviewed the CRFs of patients who died in an attempt to identify a biologically plausible explanation for the reported mortality difference. No biologically plausible explanation for a mortality imbalance was identified.
The limitations of our analysis included the following. First, most of the trials were open label. Second, the meta-analysis was not designed and did not have the power to assess mortality differences in several subgroups of interest, and as a result, the numbers of patients in subgroups with significant findings were small, making it difficult to interpret the results. Therefore, additional research will be necessary to explore potential differences in mortality for some of these subgroups. Third, because the "other" clinical conditions subset in the trial-level analysis included patients treated for a variety of infections, this population subgroup may have been more heterogeneous than others enrolled for treatment of specific conditions.
We did not find that the use of cefepime was significantly associated with increased mortality, compared with other antibacterial agents, for all trials included in our meta-analysis. Although the point estimate for the risk difference in the subset of trials including patients with febrile neutropenia did not favor cefepime, it was not statistically significant. Neither reviews of the CRFs nor analyses based on patient-level data identified a biologically plausible reason for an increased risk of mortality with cefepime use. Only adequately powered and well-controlled prospective trials may definitively answer the question of whether the use of cefepime, compared with other antibacterial agents, is associated with increased mortality.
